Table 2.
Comparison of patient characteristics depending on local treatment
| Before PSM |
After PSM |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| local treatment (n = 265) |
no local treatment (n = 587) |
local treatment (n = 184) |
no local treatment (n = 184) |
|||||||
| N | % | N | % | p value | N | % | N | % | p value | |
| Age (median, IQR) | 58 (50–67) | 58 (50–65) | 0.145 | 58 (50–68) | 60 (53–67) | 0.711 | ||||
| Sex | ||||||||||
| Male | 228 | 86.0 | 508 | 86.5 | 0.843 | 155 | 84.2 | 153 | 83.2 | 0.778 |
| Female | 37 | 14.0 | 79 | 13.5 | 29 | 15.8 | 31 | 16.8 | ||
| Diagnosis | ||||||||||
| B-viral | 192 | 72.5 | 451 | 76.8 | 0.076 | 128 | 69.6 | 142 | 77.2 | 0.247 |
| C-viral | 23 | 8.7 | 28 | 4.8 | 16 | 8.7 | 11 | 6.0 | ||
| NBNC | 50 | 18.9 | 108 | 18.4 | 40 | 21.7 | 31 | 16.8 | ||
| CPS | ||||||||||
| A | 192 | 72.5 | 318 | 54.2 | <0.001 | 127 | 69.0 | 127 | 69.0 | 1.000 |
| B | 72 | 27.2 | 247 | 42.1 | 56 | 30.4 | 56 | 30.4 | ||
| C | 1 | 0.4 | 22 | 3.7 | 1 | 0.5 | 1 | 0.5 | ||
| PVTT | ||||||||||
| Yes | 95 | 35.8 | 214 | 36.5 | 0.864 | 75 | 40.8 | 66 | 35.9 | 0.075 |
| No | 170 | 64.2 | 373 | 63.5 | 109 | 59.2 | 118 | 64.1 | ||
| Primary tumor status | ||||||||||
| Controlled | 119 | 44.9 | 51 | 8.7 | <0.001 | 38 | 20.7 | 38 | 20.7 | 1.000 |
| Not controlled | 146 | 55.1 | 536 | 91.3 | 146 | 79.3 | 146 | 79.3 | ||
| Metastasis status | ||||||||||
| LN alone | 226 | 85.3 | 306 | 52.1 | <0.001 | 145 | 78.8 | 145 | 78.8 | 1.000 |
| LN + extra-nodal metastasis | 39 | 14.7 | 281 | 47.9 | 39 | 21.2 | 39 | 21.2 | ||
| Tumor marker | ||||||||||
| AFP (median, IQR) | 42 (6–1,318) | 158 (9–2,474) | 0.048 | 88 (8–2,091) | 99 (6–1,656) | 0.892 | ||||
| PIVKA-II (median, IQR) | 313 (27–2,000) | 629 (47–2,000) | 0.038 | 483 (34–2,000) | 177 (34–2,000) | 0.356 | ||||
IQR, interquartile range; NBNC, non-B-viral non-C-viral; CPS, Child-Pugh score; PVTT, portal vein tumor thrombosis; LN, lymph node; AFP, alpha-fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence or antagonist-II.